Agoracom Blog Home

Posts Tagged ‘Cronos Group Inc’

$HOLL $HSTRF Announces Exclusive Distribution Partnership with Nabis for Expanded Market Reach Across California $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-AB at 11:20 AM on Monday, April 5th, 2021
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Hollister leverages California’s largest dispensary network and Nabis’ rapid order fulfillment for its brand portfolio

VANCOUVER, BC, April 5, 2021 /CNW/ – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) has partnered with one of California’s leading distributors, Nabis, as demand for Hollister products continues to build. The new exclusive partnership will help streamline sales, grow retail opportunities and reduce wholesale delivery times on all orders. 

Nabis supports California’s cannabis market with its wholesale distribution services. Supplying more than 99% of California’s dispensaries with a diverse selection of innovative products, Nabis works directly with brands to ensure timely fulfillment, and provides actionable sales data and insights to help brands scale and grow.

The partnership comes at a time when Hollister’s portfolio of products continues to gain brand awareness. HashBone, a hash-infused pre-roll, is one of the company’s signature products in California, and Hollister recently acquired one of Arizona’s leading concentrate brands, Venom Extracts, which is coming soon to the California market. This month, Hollister will introduce Easyriders pre-rolls in a collectible tin as the first products from its collaboration with the iconic motorcycle lifestyle magazine. Hollister also has product collaborations with Tommy Chong and the veterans-aligned medicinal brand Tactical Relief. 

“We are excited to be partnered with Nabis for our last mile fulfillment. Nabis has built a best-in-class last-mile fulfillment business that will help Hollister’s brands reach more California dispensaries with reduced lead times,” says Carl Saling, the Co-Founder, CEO and Director of Hollister Biosciences.

“While Nabis works with a wide range of cannabis brands, we always have our eye on companies with well established and diverse brand portfolios as potential partners,” said Jun S. Lee, President of Nabis. “Hollister Cannabis Co. joining our family of Nabis-distributed brands is a great partnership for all parties. We look forward to distributing Hollister’s high-profile, top-quality products to dispensaries across California.”

To read more, click here.

CLIENT FEATURE: $HOLL $HSTRF Powering Class-leading #Cannabis Products From Seed to Shelf $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-AB at 2:46 PM on Wednesday, March 17th, 2021

CLIENT FEATURE: Hollister Biosciences Inc. (HOLL: CSE)Acquiring, developing and powering class-leading cannabis consumer products.

WHY HOLLISTER?

  • Vertically integrated, high-margin cannabis company with high-quality cannabis and hemp products in over 280 dispensaries throughout California and over 90 dispensaries throughout Arizona, plus joint ventures, licensing agreements, and partnerships with global brands.
  • Hollister controls the whole process from manufacturing to sales, to distribution. From seed to shelf. 
  • Fully licensed and compliant and have established a statewide distribution within California for medical and recreational cannabis.
  • The U.S. market for cannabis-infused drinks is expected to grow to $1.4 billion by 2024. Zenith Global.
  • The market for hemp-derived CBD products was USD $591 Million in 2018, expected to reach USD $22 Billion by 2022.

Recent Highlights:

Q4 2020 Financial Highlights:

Q4 2020 Performance Includes CDN $14.93 Million in Revenue With an Estimated CDN $2.53 Million in EBITDA a YoY Revenue Increase of 3215% from Q4 2019

March:

February:

January

December:

Market Analysis/Overview:

What is Hollister?

  1. Hollister Biosciences Inc. is a multi-state company with a portfolio of innovative, high-quality cannabis & hemp branded consumer products and white-labelling manufacturing. Products are sold in 370 dispensaries across Arizona and California.
  2. Hollister Biosciences owns 100% of Venom Extracts, a category-leading brand that sold over 4 million grams in 2020, accounting for up to 30 percent of category sales in Arizona.
  3. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. 
  4. The wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

What Brands Does Hollister Own?

Hollister $HOLL.ca $HSTRF 

$CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Hollister Biosciences Inc. is traded on the CSE as HOLL.

For more information, visit: https://hollisterbiosciences.co/investors/

FULL DISCLOSURE: Hollister Biosciences Inc. is an advertising client of AGORA Internet Relations Corp.

Dreamy Delivery Announced as the Official Delivery Platform of the 2021 Emerald Cup Awards

Posted by AGORACOM-AB at 6:38 PM on Monday, March 8th, 2021
Hollister Biosciences Inc. | CSE - Canadian Securities Exchange
  • Hollister’s direct-to-consumer delivery platform, Dreamy Delivery, will be the official delivery platform of the 2021 Emerald Cup Awards
  • “The Emerald Cup Awards have been the premier Cannabis Cup in California for 17 years. It is a huge part of the fabric of cannabis in Northern California. We are excited and honored to be the official delivery platform of The Emerald Cup Awards,” Carl Saling, Co-Founder, CEO and Director of Hollister Biosciences, said.

VANCOUVER, BC, March 8, 2021 /PRNewswire/ – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) is pleased to announce that its direct-to-consumer delivery platform, Dreamy Delivery, will be the official delivery platform of the 2021 Emerald Cup Awards.  Dreamy Delivery will feature prominently in all Emerald Cup promotions and coverage, and it will help connect Bay Area, Sacramento, Hollister and Central Coast consumers with the brands participating in the virtual awards this April.

“The Emerald Cup Awards have been the premier Cannabis Cup in California for 17 years. It is a huge part of the fabric of cannabis in Northern California. We are excited and honored to be the official delivery platform of The Emerald Cup Awards,” says Carl Saling, the Co-Founder, CEO and Director of Hollister Biosciences.

“We’re excited to have Dreamy Delivery as our sponsor for this year’s Emerald Cup. We share the same values of vetting only the best cannabis products, best business practices, supporting social equity and offering a 5-Star experience. We are honored collaborating together this year.” ~Tim Blake, Founder of The Emerald Cup

For the first time in Emerald Cup history, the awards will be a virtual global event streaming on the Social Club TV network. Whether NoCal consumers want to sample the brands taking home the top trophies or try past winners, Dreamy Delivery brings these best-in-class products directly to their front doors utilizing all of the recommended safety protocols. This means virtual participants can experience the 17th-annual event with actual winning products delivered directly and safely to their homes. 

As the official delivery platform for the awards, Dreamy Delivery will feature prominently in a six-month promotion that includes social media posts, newsletters, PR statements and brand placement in the title card and afterparty.

The Emerald Cup Awards (described as the “Academy Awards of Cannabis” by Rolling Stone) celebrate the best emerging and established brands, and a slate of hand-picked judges selects winners that are announced daily during Take Over Week ahead of the official awards celebration. The coverage will culminate in the Social Club TV-broadcasted ceremony on Sunday, April 11, 2021 with the top honors given out in the prestigious cannabis flower categories.

About The Emerald Cup

The Emerald Cup is Northern California’s premier cannabis destination. While advancing the concept of sustainable, outdoor farming, its reputation is firmly solidified as the largest, most respected, outdoor cannabis competition in the world. As a group, The Emerald Cup prides itself in bringing together experts and educators in the cannabis industry to our fellow farmers, patients, and patrons each year.

It is a community celebration that has grown to become a global movement honoring the year’s finest, organic, sun-grown, cannabis harvest.

To read more, click here.

$HOLL Announces Closing of $7.9M Private Placement of Special Warrants, Including Full Exercise of Agents’ Option $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-AB at 3:39 PM on Tuesday, March 2nd, 2021
Hollister Biosciences Inc. | CSE - Canadian Securities Exchange
  • The Company has now closed the brokered private placement of 21,635,094  Special Warrants and raised gross proceeds of $7,896,809.31

VANCOUVER, BC – March 2, 2021 – Hollister Biosciences Inc. (CSE:HOLL, OTC:HSTRF, FRANKFURT:HOB) (“Hollister” or the “Company”) is pleased to announce, further to its news releases of January 21, 2021, and January 20, 2021, that the Company has now closed the brokered private placement of 21,635,094  Special  Warrants of the  Company  (the  “Special  Warrants”)  at a  price of  $0.365  per  Special  Warrant and raised gross proceeds of $7,896,809.31 (the “Offering”), including 3,825,094 Special Warrants sold pursuant to the exercise in full of the agents’ option granted to the Agents (as defined herein).

Eight Capital acted as sole bookrunner and lead agent on behalf of a syndicate of agents including Haywood Securities Inc. and Paradigm Capital Inc. (together with Eight Capital, the “Agents”) under the Offering.

Each Special Warrant will be automatically exercisable into units of the Company (the “Units”), as described below. Each Unit consists of one common share of the Company (a “Share”) and one-half of one common share purchase warrant (each full warrant, a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Share at a price of $0.50 per Share on or before January 2, 2025, being 46 months following the date of closing of the Offering (the “Closing Date”).

Each Special Warrant will be automatically exercisable, for no additional consideration, into Units on the date (the “Automatic Exercise Date”) that is the earlier of: (i) the date that is three business days following the date on which the Company either (A) obtains a receipt from the applicable securities regulatory authorities (the “Securities Commissions”) for a (final) short form prospectus qualifying distribution of the Units underlying the Special Warrants (the “Qualifying Prospectus”); or (B) files a supplement to a (final) short form base shelf prospectus qualifying the distribution of the Units underlying the Special Warrants (the “Qualifying Supplement”), and (ii) July 3, 2021, being the date that is four months and one day after the closing of the Offering.

Notwithstanding the foregoing, in the event the Company has not received a receipt from the Securities Commissions for the Qualifying Prospectus or filed a Qualifying Supplement on or before March 12, 2021, each holder of Special Warrants shall thereafter be entitled to acquire an additional one-half of one (0.5) Warrant for each Unit to be issued to such holder upon the automatic exercise of the Special Warrants, such that each Unit shall be comprised of one Share and one whole Warrant (collectively, the “Penalty Warrants”), without further payment or action on the part of the holder.

In connection with the Offering, the Company paid the Agents $651,084.20 in commissions and advisory fees and issued 1,441,580 special broker warrants (the “Special Broker Warrants”) to the Agents. Each Special Broker Warrant is automatically exercisable into one broker warrant (a “Broker Warrant”) for no additional payment on the Automatic Exercise Date. Each Broker Warrant will be exercisable into one Unit, subject to adjustment, at $0.365 per Unit for a period of 24 months from the closing of the Offering. Each Unit is comprised of one Share and one-half of one Warrant.

All securities issued in connection with the Offering are subject to a statutory hold period of four months plus a day in accordance with applicable securities legislation ending on July 3, 2021. The net proceeds received from the Offering will be used for working capital and general corporate purposes.

Read more HERE.

Hollister Biosciences Inc. $HOLL.ca $HSTRF Commends the State of Arizona for starting Adult-Use Cannabis Sales ahead of schedule, Venom Extracts it’s 100% owned subsidiary is a category leader with over 4 million grams sold throughout the state in 2020 $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 8:21 AM on Monday, January 25th, 2021
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Branded Products now on sale in over 370 cannabis dispensaries in Arizona and California
  • 4 owned brands, and 3 brand collaborations
  • Over 4 million grams sold
  • Over 96,000 lbs. of cannabis biomass converted into finished products in Arizona
  • Total sales for 2020 increased 3233% from 2019 and are estimated to be approximately CDN $40 million
  • December 2020 sales totaled greater than CDN$6 million

VANCOUVER, BC , Jan. 25, 2021 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, “Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 98 dispensaries throughout Arizona , is pleased to commend the state of Arizona for its efficient activation of adult-use cannabis sales. Legal sales of adult use cannabis in Arizona commenced mid-day on Friday January 22 nd , 2021, several months ahead of industry expectations, and the fastest that any of the 15 states with recreational marijuana has gone from voter approval to actual sales.

The company’s wholly owned subsidiary, Venom Extracts (” Venom “) product suite is a category leader with over 4 million grams sold in 2020, accounting for up to 30 percent of category sales state-wide. Venom is positioned for continued growth in Arizona , it has a strong brand recognition and distribution network, its products are available at leading retailers including Harvest Health and Recreation (CSE: HARV , OTCQX: HRVSF ), Curaleaf (CSE: CURA , OTCQX: CURLF ), Bloom, MuV and Oasis Cannabis dispensaries among others.

Arizona voted to legalize adult use cannabis in November, “Marijuana Business Daily projects that the state’s recreational market could generate up to $400 million in revenue its first year and more than $700 million by 2024”.

Read More: https://agoracom.com/ir/HollisterBiosciences/forums/discussion/topics/753842-hollister-biosciences-inc-commends-the-state-of-arizona-for-starting-adult-use-cannabis-sales-ahead-of-schedule-venom-extracts-it-s-100-owned/messages/2300014#message

Hollister Biosciences Inc. $HOLL.ca $HSTRF Announces an Increase in Private Placement to $6.5 Million $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 12:46 PM on Thursday, January 21st, 2021
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

  • Announced that it has entered into an amended letter of engagement with Eight Capital, pursuant to which Eight Capital, acting as sole bookrunner and lead agent, has now agreed to offer for sale, together with a syndicate of agents 17,810,000 Special Warrants of the Company on a “best efforts” private placement basis, subject to all required regulatory approvals, at a price per Special Warrant of $0.365 for total gross proceeds of up to $6,500,650
  • Each Special Warrant shall be automatically exercisable into units of the Company, as described below. Each Unit shall consist of one common share of the Company and one-half of one common share purchase warrant

VANCOUVER, British Columbia, Jan. 21, 2021 — Hollister Biosciences Inc. (CSE:HOLL, OTC:HSTRF, FRANKFURT:HOB) (“ Hollister ” or the “ Company ”) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, pursuant to which Eight Capital, acting as sole bookrunner and lead agent, has now agreed to offer for sale, together with a syndicate of agents (together with Eight Capital, the “ Agents ”), 17,810,000 Special Warrants of the Company (the “ Special Warrants ”), on a “best efforts” private placement basis, subject to all required regulatory approvals, at a price per Special Warrant of $0.365 (the “ Issue Price ”) for total gross proceeds of up to $6,500,650 (the “ Offering ”).

Each Special Warrant shall be automatically exercisable into units of the Company (the “ Units ”), as described below. Each Unit shall consist of one common share of the Company (a “ Share ”) and one-half of one common share purchase warrant (each full warrant, a “ Warrant ”). Each Warrant shall entitle the holder thereof to acquire one Share at a price of $0.50 per Share for a period of 46 months following the Closing Date.

Each Special Warrant shall be automatically exercisable, for no additional consideration, into Units on the date (the “ Automatic Exercise Date ”) that is the earlier of: (i) the date that is three business days following the date on which the Company either (A) obtains a receipt from the applicable securities regulatory authorities (the “ Securities Commissions ”) for a (final) short form prospectus qualifying distribution of the Units underlying the Special Warrants (the “ Qualifying Prospectus ”); or (B) files a supplement to a (final) short form base shelf prospectus qualifying the distribution of the Units underlying the Special Warrants (the “ Qualifying Supplement ”), and (ii) the date that is four months and one day after the Closing of the Offering.

Read More: https://agoracom.com/ir/HollisterBiosciences/forums/discussion/topics/753581-hollister-biosciences-inc-announces-an-increase-in-private-placement-to-6-5-million/messages/2299280#message

Hollister Biosciences Inc. $HOLL.ca $HSTRF Provides Update on Q4 2020 Performance Including CDN $14.93 Million in Revenue With an Estimated CDN $2.53 Million in EBITDA a YoY Revenue Increase of 3215% from Q4 2019 $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 7:44 AM on Friday, January 8th, 2021
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • For the period beginning October 1 st , 2020 and ending December 31 st , 2020, Hollister reports that it generated record quarterly revenue of CDN$14.93 million and CDN$2.53 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products.
  • “We are very pleased with our ability to deliver record quarterly revenue in such a challenging market environment. We attribute our revenue growth to further penetration of the California and Arizona dispensary networks and successful new product launches with our joint venture partners. Sales of cannabis related products continue to show resilience throughout the COVID-19 pandemic. We hope to continue this positive momentum into 2021” stated Alex Somjen , President.

VANCOUVER, BC , Jan. 7, 2021 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 90 dispensaries throughout Arizona , is pleased to provide an update on its Q4, 2020 performance.

Q4 2020 Update

For the period beginning October 1 st , 2020 and ending December 31 st , 2020, Hollister reports that it generated record quarterly revenue of CDN$14.93 million and CDN$2.53 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products. The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.

“We are very pleased with our ability to deliver record quarterly revenue in such a challenging market environment. We attribute our revenue growth to further penetration of the California and Arizona dispensary networks and successful new product launches with our joint venture partners. Sales of cannabis related products continue to show resilience throughout the COVID-19 pandemic. We hope to continue this positive momentum into 2021” stated Alex Somjen , President.

Read More: https://agoracom.com/ir/HollisterBiosciences/forums/discussion/topics/752594-hollister-biosciences-inc-provides-update-on-q4-2020-performance-including-cdn-14-93-million-in-revenue-with-an-estimated-cdn-5-53-million-in/messages/2296579#message

Hollister Biosciences Inc.’s $HOLL.ca $HSTRF Direct to Consumer #Cannabis Delivery Platform, Dreamy Delivery Launches 2nd Depot in Sacramento, California $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca $ALID

Posted by AGORACOM-JC at 7:41 AM on Tuesday, December 22nd, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Announced the launch of its 2nd fulfillment depot for its direct-to-consumer cannabis delivery platform, Dreamy Delivery
  • Company soft launched Dreamy Delivery to friends and family in the San Francisco Bay Area of Northern California , to ensure a seamless customer experience in early Q4 of 2020.
  • The Company has expanded the Platform, with Dreamy now successfully delivering to legal cannabis consumers in the San Francisco Bay Area of Northern California and now Sacramento , California.

VANCOUVER, BC , Dec. 22, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co. ” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 80 dispensaries throughout Arizona , is pleased to announce the launch of its 2nd fulfillment depot for its direct-to-consumer cannabis delivery platform, Dreamy Delivery (” Dreamy ” or the ” Platform “).

The Company soft launched Dreamy Delivery to friends and family in the San Francisco Bay Area of Northern California , to ensure a seamless customer experience in early Q4 of 2020. The Company has expanded the Platform, with Dreamy now successfully delivering to legal cannabis consumers in the San Francisco Bay Area of Northern California and now Sacramento , California. The Company hopes to launch Dreamy in the Central Coast of California by early Q1 of 2021 with the ultimate goal of delivering Cannabis statewide.

Carl Saling , CEO of Hollister , shared, “Very excited to have opened our 2nd direct to consumer delivery depot in record time, allowing us to serve legal adults in the Sacramento Area . This furthers our quest to be a dominate direct to consumer delivery platform in California .”

Website: www.dreamydelivery.com

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com .

Hollister Biosciences Inc. $HOLL.ca $HSTRF Signs Exclusive Agreement with Easyriders to Design, Manufacture and Produce a National Cannabis Product Line $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 7:32 AM on Tuesday, December 15th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Landmark Deal Establishes Iconic Pairing of Cannabis and Motorcycle Cultures

  • As part of Easyriders’ 50th-anniversary celebration, the Company signed an exclusive agreement with Hollister Biosciences to introduce a national line of cannabis products that embody the biker spirit and ethos.
  • It is anticipated that the new line will make its debut next month with pre-rolls and mini pre-rolls, followed by a cannabis tattoo balm that’s applied directly to the skin after new ink, with a full line of products coming in 2021.

VANCOUVER , Dec. 15, 2020 – Hollister Biosciences Inc. (CSE: HOLL ) (OTC: HSTRF ) ( FRANKFURT : HOB ) (the ” Company “, ” Hollister Cannabis Co. ” or ” Hollister “) has its roots in the birthplace of the American biker, and Easyriders has been the definitive voice of motorcycle culture for half a century. As part of Easyriders’ 50th-anniversary celebration, the Company signed an exclusive agreement with Hollister Biosciences to introduce a national line of cannabis products that embody the biker spirit and ethos.  It is anticipated that the new line will make its debut next month with pre-rolls and mini pre-rolls, followed by a cannabis tattoo balm that’s applied directly to the skin after new ink, with a full line of products coming in 2021.

The Company feels the market potential for these products is significant, but so is the cultural significance considering the two companies involved.

Easyriders magazine debuted shortly after the groundbreaking 1969 film Easy Rider in which Peter Fonda and Dennis Hopper portray bikers traveling across the American Southwest. Similarly, Hollister Biosciences is based in Hollister, California , home to an infamous 1947 biker rally that birthed the outlaw biker image and inspired the Marlon Brandon film The Wild One . Cannabis, which had developed its own outlaw culture a few decades before, became a staple among bikers in the late ’60s onward. As epitomized in the pages of Easyriders, this vibrant biker culture grew beyond its outlaw origins to inspire an independent spirit that embraces exploration, Americana and the sense of freedom that only comes from riding.

This is a culture that accepts nothing less than total authenticity. That includes its choice in cannabis, and that is why Hollister Biosciences and Easyriders were destined to take this ride together. From their historic roots in biker culture to their embrace of its visual iconography, these companies will offer the first truly authentic cannabis products for one of the most iconic cultures in modern American history.

“My vision for Hollister has always been to pay homage to the amazing biker culture that has permeated the global landscape over the past few decades by combining it with amazing cannabis products,” says Carl Saling , the Co-Founder, CEO and Director of Hollister Biosciences. “Easyriders is one of the most iconic and recognizable global biker brands. We are proud to be their exclusive cannabis partner, and we look forward to producing a truly authentic experience across the cannabis SKUs we develop and distribute across America.”

Hollister Biosciences, whose products are currently found in nearly 300 dispensaries in California and more than 80 in Arizona , takes a seed-to-shelf approach that carefully scales up small-farm style production that meets the highest quality standards. As part of the new agreement, the company will introduce Easyriders pre-rolls and tattoo balms into the California market in early 2021 with a full line of products to follow. Like an eastbound ride on Route 66, Arizona comes next, and the rest of the American markets will follow.

Pepper Foster, President of Easyriders, stated, “My vision for Easyriders has been to pay homage to the 50 years of this iconic magazine and to Joe Teresi who launched Easyriders in the late 1960s. The first magazine hit the stands in June 1970 , and 50 years later, we are proud to carry the torch, expanding upon that yen to be devoid of restraint by taking a broader look at what it means to be a biker in the 21st century while staying connected to our original roots. In continuing our commitment to authenticity, we are proud and excited to partner with another iconic brand, Hollister . We invite you to take the ride with us. Ride hard. Ride fast.”

The terms of the deal are; 2-year exclusive agreement on all cannabis products in the US with an 80:20 net revenue split in favour of Hollister with options to renew for subsequent terms.

About Easyriders

In 1970, Easyriders established itself as a platform for motorcycle enthusiasts to immerse in the rugged, on-the-road lifestyle championed by the counterculture movement and greats like Steve McQueen , Peter Fonda and Dennis Hopper . Issues of civil rights, the Vietnam War (and ensuing protests), political scandal and the emerging generation gap fueled our obsession with wind-swept freedom and ingrained Easyriders with its overarching sense of rebellion.

More than a magazine, Easyriders is a lifestyle.

In celebration of our 50th anniversary, we are shifting with the times and expanding the brand to encompass exclusive, major-label product collaborations; insider events and music festivals; and a quarterly coffee table–style book — that’s four thick issues per year jam-packed with gorgeous photography and feature stories.

With a nod to our roots in independence, passion and freedom, and with newfound emphasis on international travel, design and entertainment, Easyriders has flown full throttle into a new era. Join us as we embark on this next journey.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high-margin model that controls the whole process from manufacture to sales to distribution for what’s best described as seed-to-shelf cannabis. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the first state and locally licensed cannabis company in the city of Hollister, California , birthplace of the “American Biker.”

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Allied Corp. and Hollister Biosciences $HOLL.ca $HSTRF Have Now Delivered TACTICAL RELIEF Products into Distribution $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca $ALID

Posted by AGORACOM-JC at 11:14 AM on Monday, December 14th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Under the arrangement, Allied’s Tactical Relief™ branded products will be sold in licensed dispensaries across California.
  • Through their extensive distribution network, Hollister’s other brands have brought in excess of $40 million revenue between January and December 2020.
  • Allied has contributed the veteran brand, artwork, logos, packaging design and marketing for all Tactical Relief™ products.
  • Hollister has completed all aspects of production and procurement of underlying materials.
  • Allied will be supporting the marketing and brand presence with authentic veteran representation.

KELOWNA, British Columbia, Dec. 14, 2020 — Allied Corp. (“Allied”) ( OTCQB: ALID ) – an international medicinal cannabis company focused on creating and providing targeted cannabinoid health solutions to address PTSD, anxiety, stress and inflammation of the body is pleased to follow on the press release of June 26, 2020 announcing a distribution deal with Hollister Biosciences. Under the arrangement, Allied’s Tactical Relief™ branded products will be sold in licensed dispensaries across California. Through their extensive distribution network, Hollister’s other brands have brought in excess of $40 million revenue between January and December 2020. This statement is supported by Hollister’s press release of Dec 09, 2020.

Allied has contributed the veteran brand, artwork, logos, packaging design and marketing for all Tactical Relief™ products. Hollister has completed all aspects of production and procurement of underlying materials. Allied will be supporting the marketing and brand presence with authentic veteran representation.

“We are excited to partner with Hollister to bring our innovative and differentiated line up of quality Tactical Relief™ products to consumers in Hollister’s distribution network. Hollister has a proven track record of bringing successful products to market. The potential market for Tactical Relief™ products in the states that Hollister distributes to is substantial. Together, we hope to build a solid recurring revenue pipeline,” said Calum Hughes, Founder & CEO of Allied Corp.

“Tactical Relief™ is Allied’s flagship brand targeting PTSD, a debilitating condition that is all too common amongst people who are often serving in the front lines,” said Adam Smith, a Green Beret, veteran, and US representative at Allied. “We are excited to be partnering with Hollister to greatly expand Tactical Relief’s reach to those suffering from the serious effects of PTSD.”

“We are very excited to be launching Tactical Relief™ to Veterans, 1 st responders, and others suffering from PTSD through our distribution network,” said Carl Saling, Founder, CEO and Director of Hollister Biosciences Inc.

Investor Relations:
[email protected]
1-877-255-4337

About Allied Corp.
Allied Corp. is an international medical cannabis production company with a mission to address today’s medical issues by researching, creating and producing targeted cannabinoid health solutions. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products.

About Tactical Relief: https://tacticalrelief.com/cbdproducts/
Tactical Relief™ is a lifestyle brand that focuses on the licensing, development, and marketing of products around its life-style message for those suffering from symptoms of post-traumatic stress and traumatic brain injury. Specifically, Tactical Relief™ provides products and resources to veterans and first responders.

About Hollister Biosciences Inc.
Hollister Biosciences Inc. ( CSE: HOLL ) is a California based vertically integrated cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality California-grown cannabis and hemp products. Hollister uses a vertically integrated, high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker.”

Forward-Looking Statements:
This press release contains “forward-looking information” within the meaning of applicable securities laws in Canada or “forward-looking statements” made pursuant to the “safe harbour” provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking information”). Forward-looking information may relate to the Company’s future outlook and anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. The forward-looking information contained in this press release is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward looking statements in this press release include the following: that Allied is leveraging the conditions in its Colombia grow operation and future Kelowna location to support its Research and Development efforts; that Allied is making important strides forward to position itself as a leader in the medical cannabis space, that Allied intends to make a series of proposed trademark and other intellectual property protection filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy, statements respecting the joint development, manufacturing, and introduction of TACTICAL RELIEF™ branded products, and the use of proceeds from the offering of convertible notes.

There can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Risk factors that could cause actual results to differ materially from forward-looking information in this release include: the Company’s exposure to legal and regulatory risk; the effect of the legalization of adult-use cannabis in Canada and Colombia on the medical cannabis industry is unknown and may significantly and negatively affect the Company’s medical cannabis business; that the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis are not as currently expected; that adverse changes or developments affecting the Company’s main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to completion of the greenhouse construction in Colombia, risks related to market competition; risks related to the proposed adult-use cannabis industry and market in Canada and Colombia including the Company’s ability to enter into or compete in such markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks related to the Company’s current or proposed international operations; risks related to future third party strategic alliances or the expansion of currently existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the operation of an agricultural business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant interruptions to the Company’s access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Company’s cannabis products or product liability or regulatory claims or actions involving the Company’s cannabis products; risks related to the Company’s reliance on pharmaceutical distributors; that the Company, or the cannabis industry more generally, may receive unfavourable publicity or become subject to negative consumer or investor perception; that certain events or developments in the cannabis industry more generally may impact the Company’s reputation or its relationships with customers or suppliers; that the Company may not be able to obtain adequate insurance coverage in respect of the risks that it faces, that the premiums for such insurance may not continue to be commercially justifiable or that there may be coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become subject to liability arising from fraudulent or illegal activity by its employees, contractors, consultants and others; that the Company may experience breaches of security at its facilities or losses as a result of the theft of its products; risks related to the Company’s information technology systems; that the Company may be unable to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding; risks related to, or associated with, the Company’s exposure to reporting requirements; risks related to conflicts of interest; risks related to fluctuations in foreign currency exchange rates; risks related to the Company’s potential exposure to greater-than-anticipated tax liabilities; risks related to the protection and enforcement of the Company’s intellectual property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellectual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses may not be profitable; as well as any other risks that may be further described in and the risk factors discussed in the Company’s continuous disclosure including its Management’s Discussion and Analysis sections in its Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K filed under the Company’s profile at www.sec.gov.

Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this release represents the Company’s expectations as of the date of this release or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention, obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.